Primrose Bio Secures Major Investment from 1315 Capital
Slice of Manufacturing Team
Jun 25, 2024
Key Highlights:
- Primrose Bio secures investment from 1315 Capital, a leading healthcare-focused equity firm.
- Funds to enhance development of Prima RNApols™, Pfenex Expression Technology®, and PeliCRM®.
- Prima RNApols™ boosts mRNA manufacturing yields by up to 5x.
- Pfenex Expression Technology® achieves 10-20x higher yields in drug production.
- PeliCRM® is the only commercial CRM197 vaccine carrier protein.
Source (PR Newswire)
Quotes
“ "We are thrilled to have the support of such a high-quality organization and team at 1315 Capital who share our vision of expanding opportunities in biomanufacturing technologies for the pharmaceutical industry." ”
Dr. Helge Zieler, CEO at Primrose Bio
Our Take:
Primrose Bio's recent investment from 1315 Capital marks a pivotal moment in biomanufacturing innovation. With this substantial financial backing, Primrose is well-positioned to advance its cutting-edge technologies, such as Prima RNApols™, which significantly enhances mRNA production, and Pfenex Expression Technology®, which offers superior yields in drug manufacturing. This partnership not only underscores the value of Primrose’s platforms but also highlights a growing recognition of the need for more efficient and scalable production methods in the pharmaceutical industry. The strategic support from 1315 Capital will undoubtedly propel Primrose Bio to new heights, reinforcing its role as a leader in biomanufacturing solutions.
